why choose us

First received: February 20, 2023

Clinical Trial: Study of TU2218 in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

Study Status: Completed

Recruit Status: RECRUITING

Condition: Solid Tumor

Study Type: INTERVENTIONAL


Official Title: A Phase 1b/2a Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of TU2218, an Oral TGF?R Serine/Threonine Kinase Inhibitor, Administered in Combination With Pembrolizuma

Brief Summary: This study consists of phase 1b and 2a to evaluate safety, Pharmacokinetics, and efficacy of TU2218 in combination with Pembrolizumab in patients with advanced solid tumors.The main purpose of phase 1b is to determine the RP2DC of TU2218 and Pembrolizumab while the main purpose of phase 2a is to evaluate the antitumor efficacy of TU2218 in combination with Pembrolizumab in 3 different selected tumor type cohorts.

Read more